Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Safety and feasibility of definitive surgical resection for locoregionally advanced OHNSCC following MEDI6469 administration
研究概览
简要总结
The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.
详细描述
This phase Ib clinical trial uses MEDI6469 at various dose intervals prior to definitive surgical resection of patients with stage III and IV Oral Head and Neck Squamous Cell Carcinoma (OHNSCC) with the primary objective of determining the safety and feasibility of preoperative MEDI6469 administration. In addition, tumor tissue and peripheral blood will be obtained for exploratory immunologic end points including measurements of tumor infiltrating immune cell populations based on flow cytometry and immunohistochemistry as well as circulating immunological parameters that may correlate with changes induced by MEDI6469 administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with treatment naive, resectable, stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx who are candidates for definitive surgical resection followed by standard risk adapted adjuvant therapy.
- •Histologic or cytologic diagnosis of a primary OHNSCC with no radiological evidence of metastatic disease is acceptable. Patients with bone or cartilage invasion and any T or N stage are acceptable.
- •Patients with oral cavity primaries will be managed using conventional transoral or transcervical techniques; oropharynx or hypopharynx tumor will be managed with transoral robotic surgery; and larynx tumors (T3/T4 with thyroid cartilage invasion) will be managed by either total laryngectomy or larynx preservation surgery.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- •Laboratory values (performed within 28 days prior to enrollment) within protocol defined range
- •Ability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand the investigational nature of the study and the risks associated with the therapy.
- •No active gastrointestinal bleeding.
- •Anticipated lifespan greater than 12 weeks.
排除标准
- •Locoregionally unresectable or Metastatic disease (stage IVB)
- •Active infection.
- •Active autoimmune disease including patients with Inflammatory Bowel Disease as determined by an autoimmune questionnaire.
- •Previous treatment with mouse monoclonal antibodies
- •Need for chronic maintenance oral steroids > 5mg prednisone daily equivalent.
- •Any medical or psychiatric condition that in the opinion of the investigator would preclude compliance with study procedures.
研究组 & 干预措施
Group 1
Anti-OX40 antibody administration 3 weeks prior to surgical resection
干预措施: Anti-OX40 antibody administration (Drug)
Group 1
Anti-OX40 antibody administration 3 weeks prior to surgical resection
干预措施: Surgical Resection (Procedure)
Group 2
Anti-OX40 antibody administration 2 weeks prior to surgical resection
干预措施: Anti-OX40 antibody administration (Drug)
Group 2
Anti-OX40 antibody administration 2 weeks prior to surgical resection
干预措施: Surgical Resection (Procedure)
Group 3
Anti-OX40 antibody administration 1 week prior to surgical resection
干预措施: Anti-OX40 antibody administration (Drug)
Group 3
Anti-OX40 antibody administration 1 week prior to surgical resection
干预措施: Surgical Resection (Procedure)
结局指标
主要结局
Safety and feasibility of definitive surgical resection for locoregionally advanced OHNSCC following MEDI6469 administration
时间窗: 55 Days
Patients will be seen in clinic 7 times over 55 days to identify any possible side effects or complications thought to be related to the study drug to help identify the optimal treatment schedule.
次要结局
- Immunologic phenotypes of lymphocyte subsets(55 days)